Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

for Dupixent ® (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

Perspective from John Luo, MD Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...